Orexo investor relations material

Orexo AB, a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. The Company's strategy is to focus on developing products that reduce the risk of opioid dependence, misuse and accidental ingestion by chronic pain patients in need of effective pain management for long-lasting pain, who have been historically underserved. Furthermore, the company is differentiated by their scientifically-validated medications that treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The company's mission is to improve the lives of patients through acquisition, development and commercialization of new therapies as quickly as possible, with a focus on digital health technologies to rapidly deliver greater access to leading edge therapies.